vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $19.2M, roughly 1.7× CuriosityStream Inc.). OptimizeRx Corp runs the higher net margin — 15.6% vs -19.7%, a 35.3% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs -0.2%). OptimizeRx Corp produced more free cash flow last quarter ($7.1M vs $3.9M). Over the past eight quarters, OptimizeRx Corp's revenue compounded faster (28.0% CAGR vs 26.5%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

CURI vs OPRX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.7× larger
OPRX
$32.2M
$19.2M
CURI
Growing faster (revenue YoY)
CURI
CURI
+36.1% gap
CURI
35.8%
-0.2%
OPRX
Higher net margin
OPRX
OPRX
35.3% more per $
OPRX
15.6%
-19.7%
CURI
More free cash flow
OPRX
OPRX
$3.1M more FCF
OPRX
$7.1M
$3.9M
CURI
Faster 2-yr revenue CAGR
OPRX
OPRX
Annualised
OPRX
28.0%
26.5%
CURI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
OPRX
OPRX
Revenue
$19.2M
$32.2M
Net Profit
$-3.8M
$5.0M
Gross Margin
74.8%
Operating Margin
-17.6%
26.6%
Net Margin
-19.7%
15.6%
Revenue YoY
35.8%
-0.2%
Net Profit YoY
-34.6%
6535.9%
EPS (diluted)
$-0.07
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
OPRX
OPRX
Q4 25
$19.2M
$32.2M
Q3 25
$18.4M
$26.1M
Q2 25
$19.0M
$29.2M
Q1 25
$15.1M
$21.9M
Q4 24
$14.1M
$32.3M
Q3 24
$12.6M
$21.3M
Q2 24
$12.4M
$18.8M
Q1 24
$12.0M
$19.7M
Net Profit
CURI
CURI
OPRX
OPRX
Q4 25
$-3.8M
$5.0M
Q3 25
$-3.7M
$779.0K
Q2 25
$784.0K
$1.5M
Q1 25
$319.0K
$-2.2M
Q4 24
$-2.8M
$-78.0K
Q3 24
$-3.1M
$-9.1M
Q2 24
$-2.0M
$-4.0M
Q1 24
$-5.0M
$-6.9M
Gross Margin
CURI
CURI
OPRX
OPRX
Q4 25
74.8%
Q3 25
67.2%
Q2 25
63.8%
Q1 25
60.9%
Q4 24
68.1%
Q3 24
63.1%
Q2 24
62.2%
Q1 24
62.0%
Operating Margin
CURI
CURI
OPRX
OPRX
Q4 25
-17.6%
26.6%
Q3 25
-24.5%
7.9%
Q2 25
2.5%
10.9%
Q1 25
0.5%
-9.6%
Q4 24
-27.4%
11.2%
Q3 24
-25.8%
-40.2%
Q2 24
-20.6%
-19.9%
Q1 24
-30.4%
-25.5%
Net Margin
CURI
CURI
OPRX
OPRX
Q4 25
-19.7%
15.6%
Q3 25
-20.4%
3.0%
Q2 25
4.1%
5.2%
Q1 25
2.1%
-10.0%
Q4 24
-19.9%
-0.2%
Q3 24
-24.3%
-42.8%
Q2 24
-16.4%
-21.3%
Q1 24
-42.0%
-35.0%
EPS (diluted)
CURI
CURI
OPRX
OPRX
Q4 25
$-0.07
$0.27
Q3 25
$-0.06
$0.04
Q2 25
$0.01
$0.08
Q1 25
$0.01
$-0.12
Q4 24
$-0.05
$0.00
Q3 24
$-0.06
$-0.50
Q2 24
$-0.04
$-0.22
Q1 24
$-0.09
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$27.3M
$23.4M
Total DebtLower is stronger
$26.3M
Stockholders' EquityBook value
$41.5M
$128.3M
Total Assets
$75.7M
$176.9M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
OPRX
OPRX
Q4 25
$27.3M
$23.4M
Q3 25
$27.8M
$19.5M
Q2 25
$28.1M
$16.6M
Q1 25
$33.4M
$16.6M
Q4 24
$32.1M
$13.4M
Q3 24
$33.2M
$16.1M
Q2 24
$39.5M
Q1 24
$38.8M
Total Debt
CURI
CURI
OPRX
OPRX
Q4 25
$26.3M
Q3 25
$28.8M
Q2 25
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Q1 24
$37.8M
Stockholders' Equity
CURI
CURI
OPRX
OPRX
Q4 25
$41.5M
$128.3M
Q3 25
$47.2M
$122.3M
Q2 25
$49.8M
$119.3M
Q1 25
$58.1M
$116.3M
Q4 24
$57.8M
$117.0M
Q3 24
$62.2M
$114.5M
Q2 24
$64.8M
$121.0M
Q1 24
$67.0M
$122.5M
Total Assets
CURI
CURI
OPRX
OPRX
Q4 25
$75.7M
$176.9M
Q3 25
$74.7M
$170.3M
Q2 25
$78.7M
$169.3M
Q1 25
$85.3M
$167.8M
Q4 24
$86.2M
$171.2M
Q3 24
$87.6M
$165.2M
Q2 24
$90.9M
$172.9M
Q1 24
$94.6M
$176.4M
Debt / Equity
CURI
CURI
OPRX
OPRX
Q4 25
0.20×
Q3 25
0.24×
Q2 25
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
OPRX
OPRX
Operating Cash FlowLast quarter
$4.0M
$7.1M
Free Cash FlowOCF − Capex
$3.9M
$7.1M
FCF MarginFCF / Revenue
20.5%
22.0%
Capex IntensityCapex / Revenue
0.1%
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
OPRX
OPRX
Q4 25
$4.0M
$7.1M
Q3 25
$4.4M
$3.2M
Q2 25
$2.8M
$4.6M
Q1 25
$1.9M
$3.9M
Q4 24
$3.0M
$198.0K
Q3 24
$2.3M
$1.8M
Q2 24
$2.2M
$782.0K
Q1 24
$666.0K
$2.1M
Free Cash Flow
CURI
CURI
OPRX
OPRX
Q4 25
$3.9M
$7.1M
Q3 25
$3.2M
Q2 25
$4.6M
Q1 25
$1.8M
$3.8M
Q4 24
$181.0K
Q3 24
$1.8M
Q2 24
$737.0K
Q1 24
$2.1M
FCF Margin
CURI
CURI
OPRX
OPRX
Q4 25
20.5%
22.0%
Q3 25
12.2%
Q2 25
15.6%
Q1 25
12.2%
17.5%
Q4 24
0.6%
Q3 24
8.3%
Q2 24
3.9%
Q1 24
10.6%
Capex Intensity
CURI
CURI
OPRX
OPRX
Q4 25
0.1%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.0%
0.0%
Q1 25
0.5%
0.1%
Q4 24
0.0%
0.1%
Q3 24
0.0%
0.1%
Q2 24
0.0%
0.2%
Q1 24
0.0%
0.2%
Cash Conversion
CURI
CURI
OPRX
OPRX
Q4 25
1.41×
Q3 25
4.11×
Q2 25
3.56×
2.98×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons